parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in late spermatids	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 18	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16995

CRIP3 in dopamine neurons, braak-0.41 (p 0.273) → -0.40 (p 0.292)receipt 17003
CRIP3 in astrocytes, braak-0.87 (p 0.002) → -0.38 (p 0.308)receipt 17002

receipt 17003: CRIP3 in dopamine neurons, braak

power: full sample -0.44 (p 0.066, n 18), 95% CI -0.75 to +0.03. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.39 (p 0.107, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.60 (p 0.0080, n 18). not the mix.
skeptic: leave-one-out range -0.55 to -0.37, sign flips 0; without severely affected donors -0.44 (p 0.066, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CRIP3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 17002: CRIP3 in astrocytes, braak

power: full sample -0.55 (p 0.019, n 18), 95% CI -0.81 to -0.11. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.51 (p 0.032, n 18). holds up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.53 (p 0.023, n 18). not the mix.
skeptic: leave-one-out range -0.70 to -0.50, sign flips 0; without severely affected donors -0.55 (p 0.019, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CRIP3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts